BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 23856031)

  • 1. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models.
    Okamoto K; Kodama K; Takase K; Sugi NH; Yamamoto Y; Iwata M; Tsuruoka A
    Cancer Lett; 2013 Oct; 340(1):97-103. PubMed ID: 23856031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Human-Derived
    Schubert L; Le AT; Estrada-Bernal A; Doak AE; Yoo M; Ferrara SE; Goodspeed A; Kinose F; Rix U; Tan AC; Doebele RC
    Mol Pharmacol; 2021 Jun; 99(6):435-447. PubMed ID: 33795352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MAN2A1-FER Fusion Gene Is Expressed by Human Liver and Other Tumor Types and Has Oncogenic Activity in Mice.
    Chen ZH; Yu YP; Tao J; Liu S; Tseng G; Nalesnik M; Hamilton R; Bhargava R; Nelson JB; Pennathur A; Monga SP; Luketich JD; Michalopoulos GK; Luo JH
    Gastroenterology; 2017 Oct; 153(4):1120-1132.e15. PubMed ID: 28245430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor Activity of RXDX-105 in Multiple Cancer Types with
    Li GG; Somwar R; Joseph J; Smith RS; Hayashi T; Martin L; Franovic A; Schairer A; Martin E; Riely GJ; Harris J; Yan S; Wei G; Oliver JW; Patel R; Multani P; Ladanyi M; Drilon A
    Clin Cancer Res; 2017 Jun; 23(12):2981-2990. PubMed ID: 28011461
    [No Abstract]   [Full Text] [Related]  

  • 5. Apatinib inhibits cellular invasion and migration by fusion kinase KIF5B-RET via suppressing RET/Src signaling pathway.
    Lin C; Wang S; Xie W; Zheng R; Gan Y; Chang J
    Oncotarget; 2016 Sep; 7(37):59236-59244. PubMed ID: 27494860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective RET kinase inhibition for patients with RET-altered cancers.
    Subbiah V; Velcheti V; Tuch BB; Ebata K; Busaidy NL; Cabanillas ME; Wirth LJ; Stock S; Smith S; Lauriault V; Corsi-Travali S; Henry D; Burkard M; Hamor R; Bouhana K; Winski S; Wallace RD; Hartley D; Rhodes S; Reddy M; Brandhuber BJ; Andrews S; Rothenberg SM; Drilon A
    Ann Oncol; 2018 Aug; 29(8):1869-1876. PubMed ID: 29912274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies.
    Lipson D; Capelletti M; Yelensky R; Otto G; Parker A; Jarosz M; Curran JA; Balasubramanian S; Bloom T; Brennan KW; Donahue A; Downing SR; Frampton GM; Garcia L; Juhn F; Mitchell KC; White E; White J; Zwirko Z; Peretz T; Nechushtan H; Soussan-Gutman L; Kim J; Sasaki H; Kim HR; Park SI; Ercan D; Sheehan CE; Ross JS; Cronin MT; Jänne PA; Stephens PJ
    Nat Med; 2012 Feb; 18(3):382-4. PubMed ID: 22327622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology.
    Frett B; Carlomagno F; Moccia ML; Brescia A; Federico G; De Falco V; Admire B; Chen Z; Qi W; Santoro M; Li HY
    Angew Chem Int Ed Engl; 2015 Jul; 54(30):8717-21. PubMed ID: 26126987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel therapeutic strategies targeting bypass pathways and mitochondrial dysfunction to combat resistance to RET inhibitors in NSCLC.
    Shiba-Ishii A; Isagawa T; Shiozawa T; Mato N; Nakagawa T; Takada Y; Hirai K; Hong J; Saitoh A; Takeda N; Niki T; Murakami Y; Matsubara D
    Biochim Biophys Acta Mol Basis Dis; 2024 Aug; 1870(6):167249. PubMed ID: 38768929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors.
    Plenker D; Riedel M; Brägelmann J; Dammert MA; Chauhan R; Knowles PP; Lorenz C; Keul M; Bührmann M; Pagel O; Tischler V; Scheel AH; Schütte D; Song Y; Stark J; Mrugalla F; Alber Y; Richters A; Engel J; Leenders F; Heuckmann JM; Wolf J; Diebold J; Pall G; Peifer M; Aerts M; Gevaert K; Zahedi RP; Buettner R; Shokat KM; McDonald NQ; Kast SM; Gautschi O; Thomas RK; Sos ML
    Sci Transl Med; 2017 Jun; 9(394):. PubMed ID: 28615362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The action and resistance mechanisms of Lenvatinib in liver cancer.
    Buttell A; Qiu W
    Mol Carcinog; 2023 Dec; 62(12):1918-1934. PubMed ID: 37671815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CCDC6-RET fusion protein regulates Ras/MAPK signaling through the fusion- GRB2-SHC1 signal niche.
    Qiu T; Kong Y; Wei G; Sun K; Wang R; Wang Y; Chen Y; Wang W; Zhang Y; Jiang C; Yang P; Xie T; Chen X
    Proc Natl Acad Sci U S A; 2024 Jun; 121(23):e2322359121. PubMed ID: 38805286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanistic patterns and clinical implications of oncogenic tyrosine kinase fusions in human cancers.
    Cheong TC; Jang A; Wang Q; Leonardi GC; Ricciuti B; Alessi JV; Di Federico A; Awad MM; Lehtinen MK; Harris MH; Chiarle R
    Nat Commun; 2024 Jun; 15(1):5110. PubMed ID: 38877018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The heterogeneous transition state of resistance to RET kinase inhibitors converges on ERK1/2-driven Aurora A/B kinases.
    Hu X; Liu X; Khatri U; Wu J
    Drug Resist Updat; 2023 May; 68():100958. PubMed ID: 36990046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dabrafenib alleviates hepatotoxicity caused by lenvatinib via inhibiting the death receptor signaling pathway.
    Tao X; Cheng M; Huang X; Chen J; Zhou Y; Liu T; Zheng X; Shen N; Zhang Y; Luo P; He Q; Yan H; Huang P
    Toxicol Lett; 2024 Jun; 397():163-173. PubMed ID: 38754640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analyzing Somatic Genome Rearrangements in Human Cancers by Using Whole-Exome Sequencing.
    Yang L; Lee MS; Lu H; Oh DY; Kim YJ; Park D; Park G; Ren X; Bristow CA; Haseley PS; Lee S; Pantazi A; Kucherlapati R; Park WY; Scott KL; Choi YL; Park PJ
    Am J Hum Genet; 2016 May; 98(5):843-856. PubMed ID: 27153396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of two novel RET kinase inhibitors through MCR-based drug discovery: design, synthesis and evaluation.
    Frett B; Moccia M; Carlomagno F; Santoro M; Li HY
    Eur J Med Chem; 2014 Oct; 86():714-23. PubMed ID: 25232968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies and Recent Advances on Improving Efficient Antitumor of Lenvatinib Based on Nanoparticle Delivery System.
    Wang H; Bo W; Feng X; Zhang J; Li G; Chen Y
    Int J Nanomedicine; 2024; 19():5581-5603. PubMed ID: 38882543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Caged Ret Kinase Inhibitor and its Effect on Motoneuron Development in Zebrafish Embryos.
    Bliman D; Nilsson JR; Kettunen P; Andréasson J; Grøtli M
    Sci Rep; 2015 Aug; 5():13109. PubMed ID: 26300345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peritoneal effusion: an uncommon adverse effect of selective RET inhibitors.
    Belli C; Curigliano G
    Ann Oncol; 2024 May; 35(5):478-480. PubMed ID: 38369014
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.